These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24697826)

  • 1. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
    Rubin DT; Mody R; Davis KL; Wang CC
    Aliment Pharmacol Ther; 2014 May; 39(10):1143-55. PubMed ID: 24697826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
    Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
    Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States.
    Patel H; Lissoos T; Rubin DT
    PLoS One; 2017; 12(4):e0175099. PubMed ID: 28426675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany.
    Wilke T; Groth A; Long GH; Tatro AR; Sun D
    Clin Ther; 2020 Jan; 42(1):130-143.e3. PubMed ID: 31883702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
    Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.
    Taxonera C; Olivares D; Mendoza JL; Díaz-Rubio M; Rey E
    World J Gastroenterol; 2014 Jul; 20(27):9170-7. PubMed ID: 25083091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
    Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
    Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB
    Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.
    Rubin DT; Patel H; Shi S; Mody R
    Curr Med Res Opin; 2017 Mar; 33(3):529-536. PubMed ID: 27903084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.
    Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD
    BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn's disease and ulcerative colitis in the United States.
    Gibble TH; Naegeli AN; Grabner M; Isenberg K; Shan M; Teng CC; Curtis JR
    BMC Gastroenterol; 2023 Mar; 23(1):63. PubMed ID: 36894911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
    Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
    Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
    Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
    [No Abstract]   [Full Text] [Related]  

  • 17. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.
    Siegel CA; Yang F; Eslava S; Cai Z
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00128. PubMed ID: 32463619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.